
Tarchomińskie Zakłady Farmaceutyczne Polfa S.A.
Manufacture of pharmaceutical preparations
Overview
Tarchomińskie Zakłady Farmaceutyczne Polfa is a Polish pharmaceutical manufacturer that produces antibiotics, human insulin, dermatological medications, and dietary supplements. The company specializes in the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms, operating under cGMP standards. They also provide laboratory services, conducting over 4,000 tests annually, and supply around 25 million packages of prescription and over-the-counter products to medical facilities each year.
Financials
Revenue history (in m)
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
Financial statements were filed on time, on average 37 days early. All were audited by a statutory auditor.
- 202517/06/2026
- 202401/07/2025
- 202302/07/2024
- 202218/05/2023
- 202106/07/2022
- 202005/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Sanctions and PEP lists
| Person | List | Match | |
|---|---|---|---|
| Witold Pahl | Poseł na Sejm RP | confirmed | |
| Witold Pahl | Poseł na Sejm Rzeczypospolitej Polskiej | confirmed | |
| Anna Kącka | Członek organu spółki Skarbu Państwa | confirmed | |
| Mirosława Dawidziuk | Członek organu spółki Skarbu Państwa | confirmed |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Medicines
- Antibiotics
- Insulins
- Dermatology medicines
- Dietary supplements
- Contract manufacturing of medicines
- Laboratory services
Websites
- tzfpolfa.plStrona główna – TZF PolfaWordPressYoast SEOWWPMLNginx
Public procurement
No recorded participation in tenders.
The company is the contractor in one public sector contract, worth USD 486.22k.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Aug 26, 2026 | Fee for renting an office building at ul. Fleminga for the needs of UD Białołęka m.st Warszawy | $486,224 | Urząd Miasta Stołecznego Warszawy |
Trademarks
The company holds 122 active trademarks registered with the Polish Patent Office. 3 applications are pending. 92 marks have expired or were not registered. The first mark was filed in 1966.
| Mark | Protected until | |
|---|---|---|
| DOPSYTAR (word) | Dec 15, 2035 | |
| POLF - FLU f | Oct 15, 2035 | |
| AZONID (word) | Aug 19, 2035 | |
| VELONOX (word) | Jul 15, 2035 | |
| BAXIREN (word) | Jul 15, 2035 |
Job offers
The company has its own careers page: tzfpolfa.pl/kariera/oferty-pracy.
Authorized Representatives
Manner of representation
Joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations of will on behalf of the company. If the management board is a one-person management board, one member of the management board is authorised to make declarations of will on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 1994-08-01.
04 1240 1040 1111 0011 1071 8034
90 1020 1026 0000 1802 0384 9528
05 1240 6292 1111 0011 2038 5914
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Land (incl. perpetual usufruct) | $12.1M$12,109,493 |
Buildings and premises | $25.6M$25,594,174 |
Investment property | $22,602$22,602 |
MSiG notices
71 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Nov 3, 2026 | Shareholders' meeting convened | |
| May 26, 2026 | Shareholders' meeting convened | |
| May 6, 2026 | Shareholders' meeting convened | |
| Dec 3, 2025 | Shareholders' meeting convened | |
| Nov 18, 2025 | Shareholders' meeting convened |
Public aid
26 public aid cases recorded, with a total value of $4,944,672.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Apr 15, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $37,817$37,817 | Prezydent Miasta Stołecznego Warszawy | |
| Oct 8, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $62,602$62,602 | Prezydent Miasta Stołecznego Warszawy | |
| Jul 4, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $3,014$3,014 | Instytut Nauk Społeczno-Ekonomicznych sp. z o.o. + limited partnership |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| Integrated permit | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Biofarm sp. z o.o. | $143,422,260.45 | biofarm.pl | ||
| Zentiva Polska sp. z o.o. | $134,295,523.17 | zentiva.pl | ||
| Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - Lek S.A. | $119,621,017.71 | hasco-lek.pl | ||
| Przedsiębiorstwo Farmaceutyczne Lek-Am sp. z o.o. | $102,266,019.67 | lekam.pl | ||
| Farmak International sp. z o.o. | $101,647,142.16 | farmakinternational.pl | ||
| MSD Polska sp. z o.o. | $99,368,700.21 | msd.pl | ||
| Synoptis Pharma sp. z o.o. | $79,311,000.88 | synoptispharma.pl | ||
| Polfarmex S.A. | $73,543,379.32 | polfarmex.pl | ||
| Zakłady Farmaceutyczne Colfarm S.A. | $27,692,749.78 | colfarm.pl | ||
| Reig Jofre sp. z o.o. | $16,662,733.82 | reigjofre.pl |
Change history
| Date | Event | |
|---|---|---|
| 2020-02-13 | Share capital increase (87,590,000.00 PLN → 184,913,610.00 PLN) | |
| 2001-07-19 | Entered in the register |
FAQ
Last updated: 2026-08-03